Cellular Activation of Thromboxane Receptorsa
- 1 April 1994
- journal article
- research article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 714 (1) , 270-278
- https://doi.org/10.1111/j.1749-6632.1994.tb12054.x
Abstract
Thromboxane A2 is an abundant and potent product of arachidonic acid metabolism in human platelets. Its clinical importance is highlighted by the efficacy of aspirin, which, due to its irreversible inhibition of the enzyme PGG/H synthase, selects the anucleate platelet as a particular target for extended duration of action. A single thromboxane receptor gene has been identified by southern blot; sequence polymorphism in the gene sequence has been identified. The recombinant receptor is also subject to posttranslational modifications, which may modify its affinity for natural ligands. Pharmacological studies have suggested some heterogeneity among thromboxane receptors. These observations have been rendered more interesting by the discovery of an F prostaglandin isomer, 8-epi-PGF2 alpha, which exerts its biological effects through a thromboxane (or closely related) receptor. This isomer can be generated in a free radical-catalyzed or cyclooxygenase-dependent manner.Keywords
This publication has 21 references indexed in Scilit:
- Collaborative overview of randomised trials of antiplatelet therapy - III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patientsBMJ, 1994
- Collaborative overview of randomised trials of antiplatelet therapy - II: Maintenance of vascular graft or arterial patency by antiplatelet therapyBMJ, 1994
- Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patientsBMJ, 1994
- Alternative splicing of C-terminal tail of prostaglandin E receptor subtype EP3 determines G-protein specificityNature, 1993
- Transdermal modification of platelet function. A dermal aspirin preparation selectively inhibits platelet cyclooxygenase and preserves prostacyclin biosynthesis.Circulation, 1993
- Glomerular actions of a free radical-generated novel prostaglandin, 8-epi-prostaglandin F2 alpha, in the rat. Evidence for interaction with thromboxane A2 receptors.Journal of Clinical Investigation, 1992
- Suppression of Thromboxane A2but Not of Systemic Prostacyclin by Controlled-Release AspirinNew England Journal of Medicine, 1991
- Mechanisms of platelet activation: Thromboxane A2 as an amplifying signal for other agonistsThe American Journal of Cardiology, 1991
- Cloning and expression of cDNA for a human thromboxane A2 receptorNature, 1991
- Distinct platelet thromboxane A2/prostaglandin H2 receptor subtypes. A radioligand binding study of human platelets.Journal of Clinical Investigation, 1989